Exelixis | EXEL - Assets



Exelixis reported $2.68B in Assets for its fiscal quarter ending in July of 2025.


Assets Change Date
Acadia Pharmaceuticals USD 1.23B 93.19M Jun/2025
Agios Pharmaceuticals USD 1.47B 84.28M Jun/2025
Amgen USD 87.9B 1.47B Jun/2025
AstraZeneca USD 112.42B 6.17B Jun/2025
Bayer EUR 105.24B 3.95B Jun/2025
BioMarin Pharmaceutical USD 7.46B 309.33M Jun/2025
Bristol-Myers Squibb USD 94.68B 2.25B Jun/2025
Cytokinetics USD 1.23B 38.42M Jun/2025
Eisai JPY 1.41T 23.07B Jun/2025
Eli Lilly USD 100.92B 11.53B Jun/2025
Exelixis USD 2.68B 159.17M Jul/2025
Genmab DKK 6.46B 122M Jun/2025
Glaxosmithkline GBP 59.26B 205M Jun/2025
Incyte USD 5.82B 71.99M Jun/2025
Ionis Pharmaceuticals USD 2.99B 172.18M Jun/2025
MacroGenics USD 245.42M 16.24M Jun/2025
Merck USD 117.52B 2.4B Jun/2025
Moderna USD 12.01B 694M Jun/2025
Neurocrine Biosciences USD 3.89B 202.1M Jun/2025
Novartis USD 104.4B 4.45B Jun/2025
Pfizer USD 206.1B 1.93B Jun/2025
Sanofi 124.96B 7.84B Jun/2025
Takeda JPY 14T 243.81B Jun/2025
Ultragenyx Pharmaceutical USD 1.31B 5.66M Jun/2025
Xencor USD 879.42M 25.26M Jun/2025